Quantcast

Latest Neuroblastoma Stories

2011-06-22 10:00:00

VIENNA, June 22, 2011 /PRNewswire/ -- Vienna based biotech company APEIRON Biologics AG (Apeiron) strengthens its oncology pipeline: The company will support the clinical development of an immune therapy against high-risk neuroblastoma that is being conducted by the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). It is presently under investigation in a phase III trial across various European clinical centers. In return,...

2011-06-21 12:39:41

Two Baylor College of Medicine doctors have received support for their research from Alex's Lemonade Stand, a nonprofit group dedicated to fighting pediatric cancer. Dr. Jason Shohet, assistant professor of pediatrics "“ hematology/oncology and co-chair of Texas Children's Cancer Center's Neuroblastoma Program, received a two-year, $200,000 Innovation Award from the organization for his research on reprogramming neuroblastoma cancer stem cells. Innovation Awards are given by Alex's...

2011-06-08 15:51:00

PHILADELPHIA, June 8, 2011 /PRNewswire-USNewswire/ -- Soupy for Loopy Foundation donated $50,000 to the Cancer Center at The Children's Hospital of Philadelphia to fund research in neuroblastoma, a childhood cancer of the nervous system. The $50,000 gift will support two research projects aimed at developing more effective radiation treatments to kill neuroblastoma cells. The treatments, abbreviated as I-MIBG and MABG, selectively attack neuroblastoma tumors while minimizing injury to...

2011-05-31 07:00:00

GRAND RAPIDS, Mich., May 31, 2011 /PRNewswire/ -- The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) today announced the opening of a first-of-its-kind genomic-based clinical trial to treat and study pediatric cancer - specifically relapsed and refractory neuroblastoma. The 11-member NMTRC, housed at Van Andel Research Institute (VARI), is a nationwide network of pediatric cancer clinical trial sites that includes the National Cancer Institute, universities,...

2011-05-11 10:16:00

--The Cancer Center at Children's Hospital Pays Tribute to Longstanding Partnership During a Recognition Event -- PHILADELPHIA, May 11, 2011 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia announced today that it had received a $2 million gift awarded by Alex's Lemonade Stand Foundation (ALSF) as part of a longstanding partnership to eradicate pediatric cancer. The four-year $2 million gift will be matched by The Children's Hospital of Philadelphia for a total of $4...

2011-04-27 09:36:00

To view the Social Media Release, click here: http://smr.newswire.ca/en/canadian-cancer-society/when-cancer-strikes-the-most-vulnerable TORONTO, April 27 /PRNewswire/ - A new Canadian Cancer Society-funded study will investigate the genetic puzzle of a devastating nervous system cancer that strikes infants, and identify potential new treatments for the disease. The study is one of 52 new research projects worth more than $21 million announced today by the Society. The projects cover...

2011-04-19 08:00:00

BUFFALO, N.Y., April 19, 2011 /PRNewswire/ -- Today, H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, provided a company overview to venture capital, pharmaceutical and biotechnology industry leaders at the Celebration of Innovation Showcase 2011 hosted by the University of Florida Office of Technology Licensing at...

2011-02-07 15:58:01

Children's Hospital of Philadelphia finds new neuroblastoma target After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity. "Our study implicates this protein as a promising treatment target for high-risk neuroblastoma," said...

2011-01-18 07:00:00

BUFFALO, N.Y., Jan. 18, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today announced that its lead compound, CFAK-C4 , which is in development for the treatment of pancreatic cancer, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). Orphan status is given to drugs and biologics that are being developed to...

2010-12-01 22:50:58

At same gene site, variants may predispose to cancer and also drive disease progression Pediatric cancer researchers have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood. The study team, led by researchers at The Children's Hospital of Philadelphia, found that common variants in the LMO1 gene increase the risk of developing an aggressive form of neuroblastoma, and also mark the gene for continuing to drive the...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related